Rowlandmiller & PARTNERS.ADV Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Rowlandmiller & PARTNERS.ADV lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 70,557 shares of the company’s stock after selling 1,208 shares during the quarter. Johnson & Johnson comprises 2.2% of Rowlandmiller & PARTNERS.ADV’s investment portfolio, making the stock its 11th largest holding. Rowlandmiller & PARTNERS.ADV’s holdings in Johnson & Johnson were worth $10,313,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Christopher J. Hasenberg Inc purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $31,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $44,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $43,000. Grayhawk Investment Strategies Inc. raised its stake in shares of Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the period. Finally, Richardson Financial Services Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth about $54,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, August 5th. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. The Goldman Sachs Group cut their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Trading Up 0.2 %

Johnson & Johnson stock traded up $0.31 during mid-day trading on Thursday, hitting $164.23. The company’s stock had a trading volume of 5,878,274 shares, compared to its average volume of 7,265,732. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $165.83. The business has a 50 day moving average price of $155.01 and a 200-day moving average price of $153.38. The stock has a market cap of $395.25 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.80 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.